New pill aims to stop hair loss from lichen planopilaris

NCT ID NCT07532603

Recruiting now Disease control Sponsor: Priovant Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Apr 19, 2026 · Last updated May 16, 2026 · Updated 5 times

Summary

This study tests an oral medication called brepocitinib for adults with lichen planopilaris, a condition that causes scarring hair loss. About 342 participants will receive either the drug or a placebo to see if it reduces symptoms and improves scalp appearance. The goal is to control the disease, not cure it.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LICHEN PLANOPILARIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Clinical Trial Site
RECRUITING

Phoenix, Arizona, 85006, United States
Clinical Trial Site
RECRUITING

Portland, Oregon, 97210, United States
Clinical Trial Site
RECRUITING

Smyrna, Tennessee, 37167, United States
Clinical Trial Site
RECRUITING

Austin, Texas, 78613, United States
Clinical Trial Site
RECRUITING

Cedar Park, Texas, 78613, United States

Conditions

Explore the condition pages connected to this study.

LICHEN PLANOPILARIS